Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy

Haematologica

Volumn 95, Issue 9, 2010, Pages 1604-1607

  Lippert, Eric ^a   Etienne, Gabriel ^b   Mozziconacci, Marie Joelle ^c   Laibe, Sophy ^c   Gervais, Carine ^d   Girault, Stéphane ^e   Gachard, Nathalie ^e   Tigaud, Isabelle ^f   Dastugue, Nicole ^g   Huguet, François ^g   Fort, Marie Pierre ^b   Legros, Laurence ^h   Eclache, Virginie ⁱ   Mahon, Francois Xavier ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSTITUT BERGONIÉ   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e DUPUYTREN UNIVERSITY HOSPITAL   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g CHU PURPAN   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ AVICENNE HOSPITAL   (France)

Author keywords

Cml; Imatinib; Loss; Philadelphia positive; Y chromosome

Indexed keywords

IMATINIB;

ADULT; ARTICLE; CANCER SURVIVAL; CHROMOSOME LOSS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; EVENT FREE SURVIVAL; HUMAN; KARYOTYPE; MALE; MITOSIS; MOLECULAR EVOLUTION; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT RESPONSE; Y CHROMOSOME;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, Y; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77956832960     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019109     Document Type: Article

References (8)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med. 2006;355(23): 2408-2417.
2. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820.
3. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in good-riskchronic granulocytic leukemia. Blood. 1984;63(4):789-799.
4. Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18(3):671-684.
5. O'Dwyer M, Mauro MJ, Kurilik G, Mori M, Balleisen S, Olson S, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100(5):1628-1633.
6. Mohamed AN, Pemberton P, Zonder J, Schiffer CA. The effect of imatinib mesylate on patients with Philadelphia chromosome- positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin Cancer Res. 2003;9(4):1333-1337.
7. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003;101(10):3794-3800.
8. Pierre R, Hoagland HC. Age-associated aneuploidy: loss of the Y chromosome from human bone marrow cells with aging. Cancer. 1972;30(4):889-894.